Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
The exploratory findings came from 24 patients treated for 28 days in a study not designed to assess clinical efficacy.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Arvinas (Nasdaq: ARVN) presented final Phase 1 data showing exploratory eye-movement improvements with investigational ARV-102 in patients with Parkinson’s disease. The trial evaluated oral doses of 20 mg to 80 mg and placebo for 28 days in 24 patients. Dose-dependent increases in eye-movement amplitude compared with placebo reflected less severe hypometria, or movements falling short of their target.
Biomarkers linked to cellular waste processing and neuroinflammation decreased, while markers of synaptic integrity and axonal guidance increased. Reductions in cerebrospinal fluid LRRK2 protein were associated with improved eye-movement function and changes in these pathway biomarkers. The study was not designed to assess clinical efficacy. Arvinas said the findings support further clinical evaluation of ARV-102. Final results were presented at the 2026 International Congress of Parkinson’s Disease and Movement Disorders in Seoul.
Positive
- Minor pointDose-dependent eye-movement improvements after 28 days of ARV-102 treatment versus placebo reflected less severe hypometria.
- Minor pointCellular waste-processing biomarkers decreased during the Phase 1 trial.
- Minor pointNeuroinflammation biomarkers decreased during the Phase 1 trial.
- Minor pointSynaptic integrity and axonal guidance biomarkers increased during the Phase 1 trial.
- Minor pointCSF LRRK2 reductions were associated with eye-movement improvements and changes in pathway biomarkers.
Negative
- Minor pointClinical efficacy was not assessed by design; eye-movement findings were exploratory.
Key Figures
- Trial participants
- 24 patients
- Phase 1 trial in patients with Parkinson’s disease
- Oral dose range
- 20 mg to 80 mg
- ARV-102 doses evaluated, alongside placebo
- Treatment period
- 28 days
- Phase 1 trial
Previous Clinical trial Reports
-
ARV-102 data reported at least 50% LRRK2 degradation in CSF by day 14, maintained through day 28.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
protac technical
csf medical
lrrk2 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
– Data showed improvements in an objective measure of impaired eye movement associated with Parkinson’s disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers to these changes in oculomotor function and changes in synaptic biomarkers –
– Findings support continued evaluation of ARV-102 as a potential therapeutic approach for neurodegenerative diseases associated with LRRK2 dysregulation –
NEW HAVEN, Conn., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today presented novel data from a Phase 1 clinical trial of ARV-102, an investigational PROteolysis TArgeting Chimera (PROTAC) degrader designed to specifically target and degrade leucine-rich repeat kinase 2 (LRRK2). Final data from this trial were presented as late-breaking oral and poster presentations at the 2026 International Congress of Parkinson’s Disease and Movement Disorders® (MDS) in Seoul, Korea.
“These final data from our Phase 1 study in patients with Parkinson’s disease provide further evidence that ARV-102 reaches the central nervous system, degrades LRRK2, and modulates biological pathways relevant to neurodegenerative disease,” said Ilaria Conti, MD, Ph.D., Vice President, Clinical Research at Arvinas. “Although this study was not designed to assess clinical efficacy, we are encouraged by the exploratory dose-related changes in ocular saccadic hypometria and their associations with LRRK2 degradation and changes in pathway biomarkers. These findings support further clinical evaluation of ARV-102.”
The data presented augment Phase 1 clinical trial results shared earlier this year at AD/PD (The 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders) showing brain penetration and reductions of LRRK2 variant and expression-dependent endolysosomal and neuroinflammatory biomarkers, which have been shown to be elevated in neurodegenerative diseases, in the CSF.
The trial evaluated oral doses of ARV-102 ranging from 20 mg to 80 mg, as well as placebo, for 28 days, in a total of 24 patients with Parkinson’s disease. Notable findings include:
- Dose-dependent increases in amplitude of saccadic hypometria (ASH) observed after 28 days of ARV-102 treatment compared with placebo, reflecting less severe hypometria;
- Decreases in biomarkers associated with endolysosomal function and neuroinflammation;
- Increases in biomarkers of synaptic integrity and axonal guidance; and
- Associations between reductions in CSF LRRK2 protein levels and improvements in both oculomotor function and changes in pathway biomarkers of endolysosomal, neuroinflammatory, and synaptic function.
Additional detail on the ARV-102 data presentations at MDS 2026 follows below:
Presentation Title: Phase 1 Study of ARV-102, a PROTAC LRRK2 Degrader, in Parkinson’s Disease: Oculomotor and Biomarker Data
Session Number: 12
Session Title: Late-Breaking Abstracts: Parkinson's Disease
Session Type: Oral
Session Location: Conference Room E3, 3rd Floor
Presentation Number: LBA 15
Presentation Order: 3
Presentation Duration: 5 minutes
Date: Wednesday, October 7
Session Time: 12:30 - 13:30 ET
Presentation Title: Phase 1 Study of ARV-102, a PROTAC LRRK2 Degrader, in Parkinson’s Disease: Oculomotor and Biomarker Data
Session Type: E-Poster
Session Location: E-Poster Hall, online
Presentation Number: LBA 15
About ARV-102
ARV-102 is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) designed to cross the blood-brain barrier and specifically target and degrade leucine-rich repeat kinase (LRRK2), a large, multidomain scaffolding kinase with GTPase activity. Increased activity and over expression of LRRK2 have been implicated in the pathogenesis of neurological diseases, including LRRK2 genetic and idiopathic Parkinson’s disease and progressive supranuclear palsy (PSP). ARV-102 has been evaluated in a Phase 1 clinical trial in healthy volunteers and in patients with Parkinson’s disease.
About Parkinson’s Disease
Parkinson’s disease is a progressive brain disease that damages dopamine-producing neurons, leading to progression of symptoms including motor-related symptoms like tremors and limb stiffness, as well as non-motor symptoms including depression, sleep disorders, cognitive decline, and more. LRRK2 activity is abnormally increased in Parkinson’s disease – and both experimental studies and recent clinical data suggest that degrading LRRK2 may positively affect endolysosomal function, neuroinflammation, and synaptic function.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROteolysis TArgeting Chimera (PROTAC) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer, developed the first U.S. Food and Drug Administration (FDA)-approved PROTAC, a type of heterobifunctional protein degrader, which has been outlicensed to Rigel Pharmaceuticals, Inc. for exclusive global development, manufacturing, and commercialization.
Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal-bulbar muscular atrophy, also known as Kennedy’s disease; and ARV-6723, targeting HPK1 for advanced solid tumors. Arvinas has also advanced ARV-806, targeting KRAS G12D for solid tumors, in the clinic, and previously announced plans to seek an out-licensing agreement for any additional clinical trials of ARV-806, including dose expansion or combination clinical trials. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the potential of ARV-102, including its degradation of leucine-rich repeat kinase 2 (“LRRK2”), and its potential treatment of neurodegenerative diseases associated with LRRK2 dysregulation; oculomotor and biomarker data from the Phase 1 clinical trial of ARV-102 in Parkinson’s disease supporting continued evaluation of ARV-102 as a potential therapeutic approach for neurodegenerative diseases associated with LRRK2 dysregulation; whether degrading LRRK2 may positively affect endolysosomal function, neuroinflammation, and synaptic function; and Arvinas’ plans with respect to its clinical development programs. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas’ strategy, development plans, future operations, prospects, plans, and objectives of management and the statements identified in the prior paragraph, are forward-looking statements. The words “ability,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “target,” “goal,” “aim,” “whether,” “will,” “would,” “could,” “reliance,” “should,” “look forward,” “seek,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Arvinas may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete development for its product candidates, including ARV-102, on its current timelines or at all; risks related to clinical trial results and the interpretation thereof, including with respect to ARV-102; Arvinas’ ability to protect its intellectual property portfolio; Arvinas’ reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas’ cash and cash equivalents will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent other reports filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
jeff.boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Arvinas report about ARV-102 eye-movement results in Parkinson’s disease?
ARV-102 produced dose-dependent increases in eye-movement amplitude after 28 days compared with placebo, reflecting less severe movements falling short of their target. These exploratory changes were associated with reductions in cerebrospinal fluid LRRK2 protein. The study was not designed to assess clinical efficacy.
How was Arvinas’s Phase 1 ARV-102 trial in Parkinson’s disease conducted?
The trial evaluated oral ARV-102 doses ranging from 20 mg to 80 mg, as well as placebo, for 28 days in a total of 24 patients with Parkinson’s disease.